Shareholders who lost money in shares of Smartsheet Inc. (NYSE: SMAR) should contact Wolf Haldenstein Immediately

Smartsheet (SMAR) faces a securities class action tied to a take-private offer: a consortium of Blackstone and Vista offered $56.25/share (later raised to $56.50/share) but allegedly remained undisclosed until Smartsheet disclosed the deal on Sept. 24, 2024. The complaint alleges Smartsheet continued open-market repurchases during the class period at prices averaging $46.45/share—below the pending $56.50 offer—potentially depriving sellers of the acquisition premium. The lead-plaintiff deadline is Oct. 5, 2026, with the merger closing Jan. 22, 2025 at $56.50/share.

Analysis

This is primarily a reputational overhang on BX, not an earnings event. Any eventual settlement would likely be immaterial versus Blackstone’s fee streams and balance sheet, so the market should distinguish between legal headline noise and economic damage. The only real risk is that repeated sponsor-related litigation slightly raises the discount investors assign to deal-dependent franchises, but that effect is usually transient unless it leaks into fundraising or regulatory scrutiny.

For SMAR, there is no public-equity trading edge left; the claim is a closed-capital-structure issue. The second-order implication is broader than the single name: take-private sponsors and boards may become more conservative on buyback timing and disclosure choreography around pending strategic alternatives, which can marginally reduce the attractiveness of pre-close capital returns in future situations.

Catalyst-wise, the lead-plaintiff deadline is procedural noise; the investable inflection is motion-to-dismiss and any settlement discussion, which is a months-to-years process. The contrarian read is that the market often overprices litigation headlines for BX even when the expected cash cost is de minimis; unless the complaint widens to governance/process failures across other deals, this should fade. The thesis is falsified if BX underperforms peers on a sustained basis after the next earnings/FRE print, or if plaintiffs broaden discovery into sponsor-level controls rather than one-off transaction conduct.

Key Decisions for Investors

• No actionable SMAR trade: the public equity is effectively gone; treat this as a legacy claims process, not a market catalyst.
• If BX sells off 1-2% on the headline, buy the dip for a 1-3 month mean-reversion trade; expected legal cost is too small to matter versus fee earnings, with stop if relative underperformance persists after next earnings.
• Do not short BX on this filing alone; the best-case downside for the stock is usually sentiment-driven and short-lived, while settlement risk is unlikely to move intrinsic value.
• Watch for any complaint expansion into sponsor-process issues; only then consider a broader pair trade (short BX vs long a less deal-exposed alternatives manager) because the signal would shift from nuisance litigation to franchise-risk.